BACKGROUND We assessed and directly compared weight loss effects of sibutramine and orlistat treatment in a group of obese, poorly-controlled type 2 diabetic patients. METHODS This study recruited 34 diabetic subjects [glycohemoglobin (HbA1c) > 8%] with a body mass index of at least 27 kg/m2. A 36-week, three-phase, prospective, randomized, cross-over comparative study was conducted. In phase...

A stability-indicating HPLC method was developed and validated for the quantitative determination of orlistat in capsule dosage forms. An isocratic separation was achieved using a Perfectsil target ODS-3, 250 mm x 4.6 mm i.d., 5 microm particle size column with a flow rate of 0.7 ml/min and using a UV detector to monitor the eluate at 210 nm. The mobile phase consisted of methanol:acetonitrile:...

This study explored the predictors of weight loss following orlistat with a focus on both baseline variables and changes in beliefs and behaviours occurring over the course of taking the drug. Patients (n = 566) prescribed orlistat completed a questionnaire at baseline and after 6 months concerning their weight, beliefs and behaviours. By 6 months the majority had lost some weight and showed im...

OBJECTIVE: To determine whether or not Orlistat ingested prior to a meal causes an increased appetite response. STUDY DESIGN: A Review of three randomized controlled trials studies from 2003-2008 that were in the English language. DATA RESOURCES: Randomized controlled trials comparing the effect of Orlistat on satiety were found using PubMed, OVID, and Cochrane databases. OUTOMES MEASURED: Outc...

AIMS Drug treatments for obesity have proven efficacy from randomized trials, but their effectiveness in routine clinical practice is unknown. We assessed the effects on weight and body mass index (BMI) of orlistat and sibutramine when delivered in routine primary care. METHODS We used United Kingdom data from the Clinical Practice Research Datalink to estimate the effects of orlistat or sibu...

Background: Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in young women. PCOS affects 6% and 8% of women in reproductive age. Hyperandrogenism is the hallmark of PCOS. Clinically, it is possible to observe hirsutism, acne, androgenic alopecia, and signs of virilization. Laboratory examination reveals increased androgen levels. Excessive androgen has an important r...

PURPOSE To develop a bio-assay that would be able to directly test gastrointestinal and/or dissolution samples to determine lipase activity and inhibition by Orlistat. METHODS Enzyme assays were performed with porcine pancreatic lipase and para-Nitrophenyl Palmitate (pNPP) in pH 8.0 reaction buffer at 37°C. Substrate hydrolysis was monitored by absorbance changes at 410 nm. The dissolution of...

OBJECTIVE Moderate weight loss is recommended for overweight and obese patients with type 2 diabetes, and conjunctive use of weight loss medication has been advocated. The current study examined weight loss-dependent and -independent effects of the intestinal lipase inhibitor orlistat at 6 months of treatment, using behavioral intervention (Int) combined with randomized, double-blinded, placebo...

This paper presents a summary of the evidence review group (ERG) report into the clinical and cost-effectiveness of rimonabant for the treatment of obese or overweight patients based upon a review of the manufacturer's submission to the National Centre for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission's main evidence came from fou...

INTRODUCTION The overall incidence of obesity and its prevalence is increasing continuously. The obesity is a cardiovascular risk factor whose importance is increasing too. It is associated with many chronic conditions such as type II diabetes mellitus or cardiovascular diseases. The obesity is also implicated as a risk factor for several kinds of cancer such as esophagus, pancreas, colon, rect...